UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from __________ to __________
Commission
File Number: 001-41109
Intensity
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Delaware | | 46-1488089 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
1 Enterprise Drive, Suite 430 Shelton, CT | | 06484-4779 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s
telephone number, including area code: (203) 221-7381
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.0001 per share | | INTS | | The Nasdaq Stock Market |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer | | ☐ | | Accelerated filer | | ☐ |
Non-Accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
Emerging growth company | | ☒ | | | | |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As
of November 13, 2023, the registrant had 13,709,377 shares of common stock outstanding.
Table
of Contents
PART
I. FINANCIAL INFORMATION
Item
1. Condensed Financial Statements (Unaudited).
INTENSITY
THERAPEUTICS, INC.
Condensed
Balance Sheets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
(unaudited) | | |
(audited) | |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 6,693,825 | | |
$ | 1,311,877 | |
Marketable debt securities | |
| 8,955,316 | | |
| - | |
Prepaid expenses | |
| 971,239 | | |
| 62,924 | |
Other current assets | |
| 14,366 | | |
| 75,535 | |
Total current assets | |
| 16,634,746 | | |
| 1,450,336 | |
Right-of-use asset, net | |
| 152,605 | | |
| 139,089 | |
Other assets | |
| 28,438 | | |
| 167,738 | |
Total assets | |
$ | 16,815,789 | | |
$ | 1,757,163 | |
| |
| | | |
| | |
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 358,404 | | |
$ | 603,176 | |
Accrued expenses | |
| 355,006 | | |
| 1,723,400 | |
Current lease liability | |
| 10,556 | | |
| 143,221 | |
Convertible note and accrued interest | |
| - | | |
| 4,348,548 | |
Total current liabilities | |
| 723,966 | | |
| 6,818,345 | |
Long-term lease liability | |
| 144,891 | | |
| - | |
Related party deposit | |
| 36,000 | | |
| 36,000 | |
Total liabilities | |
| 904,857 | | |
| 6,854,345 | |
Series A redeemable convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 5,000,000 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 10,000,000 | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY (DEFICIENCY) | |
| | | |
| | |
| |
| | | |
| | |
Authorized preferred stock is 15,000,000 shares as of September 30, 2023. None issued or outstanding as of September 30, 2023. | |
| | | |
| | |
| |
| | | |
| | |
Series B convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 1,449,113 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 145 | |
| |
| | | |
| | |
Series C convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 1,800,606 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 180 | |
| |
| | | |
| | |
Common stock, par value $.0001. Authorized shares of 135,000,000 and 50,000,000 as of September 30, 2023 and December 31, 2022, respectively. Issued and outstanding shares of 13,709,377 and 3,410,103 as of September 30, 2023 and December 31, 2022, respectively. | |
| 1,371 | | |
| 341 | |
Additional paid-in capital | |
| 63,252,862 | | |
| 23,555,160 | |
Accumulated deficit | |
| (47,343,301 | ) | |
| (38,653,008 | ) |
Total stockholders’ equity (deficiency) | |
| 15,910,932 | | |
| (15,097,182 | ) |
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency) | |
$ | 16,815,789 | | |
$ | 1,757,163 | |
The
accompanying notes are an integral part of these financial statements.
INTENSITY
THERAPEUTICS, INC.
Condensed
Statements of Operations
(Unaudited)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating expenses: | |
| | |
| | |
| | |
| |
Research and development costs | |
$ | 1,351,766 | | |
$ | 1,160,737 | | |
$ | 2,984,752 | | |
$ | 4,241,203 | |
General and administrative costs | |
| 1,138,748 | | |
| 607,113 | | |
| 1,981,594 | | |
| 1,834,966 | |
Total operating expenses | |
| 2,490,514 | | |
| 1,767,850 | | |
| 4,966,346 | | |
| 6,076,169 | |
Loss from operations | |
| (2,490,514 | ) | |
| (1,767,850 | ) | |
| (4,966,346 | ) | |
| (6,076,169 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 147,539 | | |
| 988 | | |
| 148,026 | | |
| 1,844 | |
Interest expense | |
| - | | |
| (15,123 | ) | |
| (305,161 | ) | |
| (44,877 | ) |
Loss on debt extinguishment | |
| - | | |
| - | | |
| (2,261,581 | ) | |
| - | |
Other | |
| 13,230 | | |
| 7,118 | | |
| 18,304 | | |
| 47,646 | |
Net loss | |
$ | (2,329,745 | ) | |
$ | (1,774,867 | ) | |
$ | (7,366,758 | ) | |
$ | (6,071,556 | ) |
| |
| | | |
| | | |
| | | |
| | |
Preferred stock deemed dividend | |
| - | | |
| - | | |
| (1,323,535 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common stockholders | |
$ | (2,329,745 | ) | |
$ | (1,774,867 | ) | |
$ | (8,690,293 | ) | |
$ | (6,071,556 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per share, basic and diluted | |
$ | (0.17 | ) | |
$ | (0.52 | ) | |
$ | (1.26 | ) | |
$ | (1.78 | ) |
Weighted average number of shares of common stock, basic and diluted. | |
| 13,660,627 | | |
| 3,410,103 | | |
| 6,899,984 | | |
| 3,410,103 | |
The
accompanying notes are an integral part of these financial statements.
Intensity
Therapeutics Inc.
Condensed
Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity
(Deficiency)
Nine
Months and Three Months Ended September 30, 2023 and 2022
(unaudited)
| |
Series A Redeemable
Convertible Preferred Stock | | |
Series B Convertible
Preferred | | |
Series C Convertible
Preferred | | |
Common Stock | | |
Additional Paid in | | |
Accumulated | | |
Stockholders’ Equity | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
(Deficiency) | |
Balances at December 31, 2022 | |
| 5,000,000 | | |
$ | 10,000,000 | | |
| 1,449,113 | | |
$ | 145 | | |
| 1,800,606 | | |
$ | 180 | | |
| 3,410,103 | | |
$ | 341 | | |
$ | 23,555,160 | | |
$ | (38,653,008 | ) | |
$ | (15,097,182 | ) |
Stock-based compensation expense | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 975,422 | | |
| | | |
| 975,422 | |
Warrants issued to convertible note holders | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 159,262 | | |
| | | |
| 159,262 | |
Warrants issued to underwriters in connection with public offering and overallotment | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,169,719 | | |
| | | |
| 1,169,719 | |
Issuance of common stock in public offering for cash, net of $3,031,484 issuance costs | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 3,900,000 | | |
| 390 | | |
| 16,468,126 | | |
| | | |
| 16,468,516 | |
Issuance of common stock in overallotment for cash, net of $371,583 issuance costs | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 585,000 | | |
| 59 | | |
| 2,553,358 | | |
| | | |
| 2,553,417 | |
Conversion of preferred stock into common stock | |
| (5,000,000 | ) | |
| (10,000,000 | ) | |
| (1,449,113 | ) | |
| (145 | ) | |
| (1,800,606 | ) | |
| (180 | ) | |
| 4,124,851 | | |
| 413 | | |
| 9,999,868 | | |
| | | |
| 9,999,956 | |
Conversion of convertible notes into common stock | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,399,716 | | |
| 140 | | |
| 6,998,440 | | |
| | | |
| 6,998,580 | |
Exercise of options and warrants | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 25,000 | | |
| 2 | | |
| 49,998 | | |
| | | |
| 50,000 | |
Deemed dividend | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 264,707 | | |
| 26 | | |
| 1,323,509 | | |
| (1,323,535 | ) | |
| - | |
Net loss | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (7,366,758 | ) | |
| (7,366,758 | ) |
Balances at September 30, 2023 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 13,709,377 | | |
$ | 1,371 | | |
$ | 63,252,862 | | |
$ | (47,343,301 | ) | |
$ | 15,910,932 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balances at June 30, 2023 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 13,099,377 | | |
$ | 1,310 | | |
$ | 60,145,764 | | |
$ | (45,013,556 | ) | |
$ | 15,133,518 | |
Stock-based compensation expense | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 351,169 | | |
| | | |
| 351,169 | |
Warrants issued to underwriters in connection with public offering and overallotment | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 152,573 | | |
| | | |
| 152,573 | |
Issuance of common stock in connection with overallotment, net of $371,583 issuance costs | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 585,000 | | |
| 59 | | |
| 2,553,358 | | |
| | | |
| 2,553,417 | |
Exercise of options and warrants | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 25,000 | | |
| 2 | | |
| 49,998 | | |
| | | |
| 50,000 | |
Net loss | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (2,329,745 | ) | |
| (2,329,745 | ) |
Balances at September 30, 2023 | |
| - | | |
$ | - | | |
| - | | |
$ | 0 | | |
| - | | |
$ | 0 | | |
| 13,709,377 | | |
$ | 1,371 | | |
$ | 63,252,862 | | |
$ | (47,343,301 | ) | |
$ | 15,910,932 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balances at December 31, 2021 | |
| 5,000,000 | | |
| 10,000,000 | | |
| 1,449,113 | | |
$ | 145 | | |
| 1,800,606 | | |
$ | 180 | | |
| 3,410,103 | | |
$ | 341 | | |
$ | 22,386,341 | | |
$ | (31,071,111 | ) | |
$ | (8,684,104 | ) |
Stock-based compensation expense | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 541,333 | | |
| | | |
| 541,333 | |
Net loss | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (6,071,556 | ) | |
| (6,071,556 | ) |
Balances at September 30, 2022 | |
| 5,000,000 | | |
$ | 10,000,000 | | |
| 1,449,113 | | |
$ | 145 | | |
| 1,800,606 | | |
$ | 180 | | |
| 3,410,103 | | |
$ | 341 | | |
$ | 22,927,674 | | |
$ | (37,142,667 | ) | |
$ | (14,214,327 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balances at June 30, 2022 | |
| 5,000,000 | | |
| 10,000,000 | | |
| 1,449,113 | | |
| 145 | | |
| 1,800,606 | | |
| 180 | | |
| 3,410,103 | | |
| 341 | | |
$ | 22,886,963 | | |
$ | (35,367,800 | ) | |
$ | (12,480,171 | ) |
Stock-based compensation expense | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 40,711 | | |
| | | |
| 40,711 | |
Net loss | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (1,774,867 | ) | |
| (1,774,867 | ) |
Balances at September 30, 2022 | |
| 5,000,000 | | |
$ | 10,000,000 | | |
| 1,449,113 | | |
$ | 145 | | |
| 1,800,606 | | |
$ | 180 | | |
| 3,410,103 | | |
$ | 341 | | |
$ | 22,927,674 | | |
$ | (37,142,667 | ) | |
$ | (14,214,327 | ) |
The
accompanying notes are an integral part of these financial statements.
INTENSITY
THERAPEUTICS, INC.
Condensed
Statements of Cash Flows
(Unaudited)
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(7,366,758 |
) |
|
$ |
(6,071,556 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Amortization of discount on convertible notes |
|
|
159,262 |
|
|
|
- |
|
Change in carrying value of right-of-use asset |
|
|
141,108 |
|
|
|
133,605 |
|
Stock-based compensation expense |
|
|
975,422 |
|
|
|
541,333 |
|
Loss on debt extinguishment |
|
|
2,261,581 |
|
|
|
- |
|
Changes in operating assets and liabilities, net: |
|
|
|
|
|
|
|
|
Accrued interest on marketable debt securities |
|
|
(110,937 |
) |
|
|
- |
|
Prepaid expenses |
|
|
(908,315 |
) |
|
|
32,384 |
|
Other current assets |
|
|
61,169 |
|
|
|
2,353 |
|
Other assets |
|
|
139,300 |
|
|
|
- |
|
Accounts payable |
|
|
(244,772 |
) |
|
|
623,797 |
|
Accrued expenses |
|
|
(1,368,394 |
) |
|
|
986,189 |
|
Accrued interest on convertible note |
|
|
145,899 |
|
|
|
44,877 |
|
Change in lease liabilities |
|
|
(142,398 |
) |
|
|
(135,645 |
) |
Net cash used in operating activities |
|
|
(6,257,833 |
) |
|
|
(3,842,663 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchase of marketable debt securities |
|
|
(8,844,379 |
) |
|
|
- |
|
Net cash used in investing activities |
|
|
(8,844,379 |
) |
|
|
- |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible note |
|
|
242,552 |
|
|
|
- |
|
Payout of fractional shares on reverse split |
|
|
(44 |
) |
|
|
- |
|
Proceeds
from Initial Public Offering |
|
|
19,500,000 |
|
|
|
- |
|
Proceeds
from overallotment shares |
|
|
2,925,000 |
|
|
|
- |
|
Issuance
costs related to initial public offering and overallotment |
|
|
(2,233,348 |
) |
|
|
- |
|
Proceeds
from exercise of options and warrants |
|
|
50,000 |
|
|
|
- |
|
Net
cash provided by financing activities |
|
|
20,484,160 |
|
|
|
- |
|
Net increase (decrease) in cash and cash equivalents |
|
|
5,381,948 |
|
|
|
(3,842,663 |
) |
Cash and cash equivalents at beginning of period |
|
|
1,311,877 |
|
|
|
4,539,229 |
|
Cash and cash equivalents at end of period |
|
$ |
6,693,825 |
|
|
$ |
696,566 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash financing activities: |
|
|
|
|
|
|
|
|
Right-of-use lease asset and operating lease liability |
|
$ |
154,624 |
|
|
|
- |
|
Conversion of convertible notes and accrued interest into common stock |
|
$ |
4,736,999 |
|
|
|
- |
|
Warrants issued in relation to issuance of convertible notes |
|
$ |
159,262 |
|
|
|
- |
|
Warrants issued to underwriter in connection with stock issuance |
|
$ |
1,169,719 |
|
|
|
- |
|
Preferred stock deemed dividend |
|
$ |
1,323,535 |
|
|
|
- |
|
The
accompanying notes are an integral part of these financial statements.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note A — Nature of Business
Intensity Therapeutics, Inc.
(“the Company”) is Connecticut-based and incorporated in Delaware in December 2012. The Company is a biotechnology company
whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRxSM
technology platform has identified a lead drug, INT230-6.
As a result of its initial
public offering (“IPO”) that priced on June 29, 2023, the Company began trading on the Nasdaq Capital Market under the symbol
“INTS” on June 30, 2023. The IPO closed on July 5, 2023, at which time the Company issued 3,900,000 shares of our common stock and received gross proceeds of $19,500,000 less some of the issuance costs for a cash transfer
of $17,765,000. There were additional issuance costs on the IPO of approximately $264,000. The IPO shares were issued on July 5, 2023, the closing date, at the time that the net proceeds were transferred to
the Company. On July 7, 2023, the Company sold the full overallotment shares of the IPO. The overallotment resulted in the issuance of
585,000 shares of our common stock, and the Company received $2,691,000 in net cash proceeds. The Company has begun to use and will continue
to use the net proceeds from the IPO and overallotment to complete pre-clinical and clinical studies, conduct manufacturing suitable for
phase 3 studies, submit regulatory filings to the United States Food & Drug Administration (“FDA”) and for general and
corporate purposes.
On April 27, 2023, the Company
effected a two-for-one reverse stock split (the “Reverse Stock Split”). All owners of record as of April 27, 2023 received
one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common
stock. All fractional shares created by the two-for-one exchange were paid in cash. The conversion price of Series A redeemable convertible
preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock were adjusted to reflect the Reverse
Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s
common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred
stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable
upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in
the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split. All preferred stock
and convertible notes that were issued during the pre-IPO period were converted into common stock.
Note B — Liquidity and Plan of Operation
The accompanying unaudited
condensed financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation
of the Company as a going concern.
The Company is a research
and development company and has not generated any revenue from its product candidates. The Company, therefore, has experienced net losses
and negative cash flows from operations each year since its inception. Through September 30, 2023, the Company has an accumulated deficit
of approximately $47.3 million. The Company’s operations have been financed primarily through the sale of equity securities and
convertible notes. The Company’s net loss for the nine months ended September 30, 2023 was approximately $7.4 million.
To date, the Company has
not obtained regulatory approval for any of its product candidates. The Company expects to incur significant expenses to complete development
of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates
in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.
The Company does not expect to receive significant product revenue in the near term. The Company, therefore, expects to continue to incur
substantial losses for the foreseeable future.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note B — Liquidity and Plan of Operation
(continued)
Cash and cash equivalents
at September 30, 2023 totaled approximately $6.7 million. The Company’s investment in marketable debt securities totaled approximately
$9.0 million at September 30, 2023. These two accounts total approximately $15.7 million. Until such time, if ever, as the Company can
generate substantial product revenue, the Company expects to finance its operational needs through a combination of equity offerings and
convertible debt financings. The Company does not have any committed external source of funds. To the extent that the Company can raise
additional capital through the sale of equity or convertible debt securities, the ownership interest of the Company stockholders will
be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the common
stockholders. If the Company is unable to raise additional funds through equity or debt financings when needed, the Company may be required
to delay, limit, reduce or terminate its research and product development.
Based on the cash, cash equivalents, and investment
in marketable debt securities as of September 30, 2023, the Company expects its cash and cash equivalents to be sufficient to fund operations
for a period of at least 12 months from the date that these financial statements are issued.
Note C — Summary of Significant Accounting
Policies and Accounts
[1] Basis of presentation:
The accompanying condensed
financial statements include the accounts of Intensity Therapeutics, Inc. These condensed financial statements have been prepared in accordance
with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial
position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America
(“GAAP”); however, such information reflects all adjustments consisting solely of normal recurring adjustments, which are,
in the opinion of management, necessary for a fair presentation of the results for the interim periods.
The condensed financial statements
should be read in conjunction with the audited financial statements and notes included in the Company’s prospectus, dated June 29,
2023 and filed with the Securities and Exchange Commission on June 30, 2023.
[2] Use of estimates:
The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.
Certain accounting principles
require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation
could result depending on the judgments, estimates, or assumptions that are used.
The Company utilizes significant
estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are
based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue
as a going concern.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note C — Summary of Significant Accounting
Policies and Accounts (continued)
[3] Concentration of credit risk:
The Company’s financial
instruments that are exposed to concentrations of credit risk consist entirely of cash and investments in U.S. Treasury bills. These financial
instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”)
up to regulatory limits. During the nine months ended September 30, 2023 and 2022, the Company’s cash balances exceeded the FDIC
insurance limit. The investments in U.S. Treasury bills are not FDIC insured but are backed by the U.S. government. U.S. Treasury bills
are subject to market risk if they are sold prior to maturity. The Company has not experienced any losses in such accounts. Although the
Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the
Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC.
[4] Cash and cash equivalents:
The Company considers all
liquid investments with an original maturity of three months or less to be cash equivalents.
[5] Marketable debt securities:
Investments in U.S. Treasury
bills purchased with an original maturity over three months are classified separately from cash and cash equivalents in current assets.
Investments in U.S. Treasury bills are classified as available for sale. Under the classification of available for sale, securities are
reported at fair value. Unrealized gains or losses would be included in accumulated other comprehensive income within the equity section
of the Balance Sheet. At September 30, 2023, there were no unrealized gains or losses and all accrued interest was recognized as Interest
income in the Statement of Operations.
[6] Fair value measurement:
The Company reports its investments
at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value
measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used
to measure fair value into three levels:
|
Level 1 |
Unadjusted quoted prices in active markets for identical assets or liabilities. |
|
Level 2 |
Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. |
|
Level 3 |
Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. |
An asset’s or liability’s
level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability
of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and
liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note C — Summary of Significant Accounting
Policies and Accounts (continued)
[6] Fair value measurement: (continued)
At September 30, 2023, the
Company has a total of approximately $9.0 million invested in U.S. Treasury Bills: none is included in cash and cash equivalents and $9.0
million is included in marketable debt securities. U.S. Treasury bills are valued at market price. U.S. Treasury Bills are categorized
in Level 1 of their fair value hierarchy. At December 31, 2022, there were no investments in U.S. Treasury Bills.
The Company’s financial
instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term
nature of these instruments.
[7] Stock-based compensation:
The Company accounts for
stock-based compensation to employees and non-employees, which consists of stock option grants, through the Statements of Operations based
on their fair values at the date of grant.
The Company calculates the
fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee
and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are
recognized as they occur.
[8] Research and development and patent costs:
Research and development
costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents
are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and are included as
part of general and administrative expenses in the Company’s Statements of Operations.
[9] Income taxes:
The Company accounts for
income taxes through the use of the asset-and-liability method whereby deferred tax assets and liabilities are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company utilizes a valuation allowance to reduce deferred tax assets to
their estimated realizable value.
The Company accounts for
uncertain tax positions. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that
the benefit will more likely than not be realized.
The determination as to whether
the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration
of the available facts and circumstances. At September 30, 2023, the Company does not have any significant uncertain tax positions.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note C — Summary of Significant Accounting
Policies and Accounts (continued)
[9] Income taxes: (continued)
There are no estimated interest
costs and penalties provided for in the Company’s financial statements for the nine months ended September 30, 2023. If at any time
the Company should record interest and penalties in connection with income taxes, the interest and penalties will be expensed within the
income tax line.
The Company’s income
tax returns are subject to Federal, state and local income tax examination by the authorities for the last three tax years.
[10] Leases:
The Company determines if
an arrangement contains a lease at contract inception. With the exception of short-term leases (leases with terms less than 12 months),
all leases with contractual fixed costs are recorded on the balance sheet on the commencement date as a right-of-use (ROU) asset and a
lease liability. Lease liabilities to be paid over the next twelve months are classified as current lease liability and all other lease
obligations are classified as long-term lease liability. Lease liabilities are initially measured at the present value of the future minimum
lease payments and subsequently increased to reflect the interest accrued and reduced by the lease payments made. The Company’s
building leases require a pro-rata share of operating expenses and real estate taxes, which are variable in nature and excluded from the
measurement of lease liabilities. ROU assets are initially measured at the present value of the future minimum lease payments adjusted
for any prior lease pre-payments, lease incentives and initial direct costs. Certain leases contain escalation, renewal and/or termination
options that are factored into the ROU asset as appropriate. Operating leases result in a straight-line rent expense over the expected
lease term.
The Company uses its estimated
incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value
of future lease payments, if the rate implicit in the lease is not readily determinable. Consideration is given to publicly available
data for instruments with similar characteristics when calculating incremental borrowing rates. This incremental borrowing rate estimate
is based on a synthetic credit rating derived from the market capitalization of similar companies, the treasury yield curve, and corporate
yield spreads.
[11] Basic and dilutive loss per share:
Basic net loss per share
is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options,
and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per
share does not include the conversion of securities that would have an anti-dilutive effect. Potential shares of common stock issuable
upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted
weighted average shares outstanding listed in the table below because they are anti-dilutive. The basic and diluted computation of net
loss per share for the Company are the same because the effects of the Company’s convertible securities would be anti-dilutive.
All common and preferred stock participate equally in dividends and the distribution of earnings if and when declared by the Board of
Directors, on the Company’s common stock for the three and nine months ended September 30, 2022. For purposes of computing earnings
per share, all series of preferred stock are considered participating securities. Therefore, the Company must calculate basic and diluted
earnings per share using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders
and participating securities according to dividends declared and participation rights in undistributed earnings. As the preferred stockholders
have no obligation to fund losses no portion of net loss was allocated to the participating securities for the three months or nine months
ended September 30, 2022. There were no preferred shares outstanding at September 30, 2023.
At September 30, 2023 and 2022, the following shares
of common stock underlying preferred stock, options, and warrants were excluded from the computation of diluted weighted average shares
outstanding. In accordance with the Reverse Stock Split on April 27, 2023 (see Note A), the number of shares of common stock underlying
the preferred stock, options and warrants are now half, and the below information gives effect to this Reverse Stock Split:
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | |
Preferred stock Series A outstanding | |
| - | | |
| 2,499,999 | |
Preferred stock Series B outstanding | |
| - | | |
| 724,552 | |
Preferred stock Series C outstanding | |
| - | | |
| 900,300 | |
Options outstanding | |
| 1,081,750 | | |
| 851,250 | |
Warrants outstanding | |
| 689,200 | | |
| 323,250 | |
| |
| 1,770,950 | | |
| 5,299,351 | |
As of September 30, 2022
the shares that would be issued from the convertible notes outstanding are also excluded from diluted weighted average shares outstanding,
since the conversion rate is dependent upon qualified liquidity events. All convertible notes were converted into shares of common stock
on June 29, 2023.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note C — Summary of Significant Accounting
Policies and Accounts (continued)
[12] Stock issuance costs:
The Company incurred costs
related to the sale of its common stock in its IPO and the subsequent sale of common stock in the overallotment. These costs included underwriter
commissions and fees, legal fees, accounting fees, and printing costs. These costs were recorded as a deduction to Additional Paid in
Capital.
[13] Recently issued pronouncements:
The Company does not
believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material
impact on its financial statements.
[14] Reclassifications:
Certain prior year amounts
have been reclassified to conform to current year presentation.
Note D — Marketable Debt Securities
Marketable debt securities
consist of U.S. Treasury bills purchased with original maturities of at least three months, but less than twelve months. Securities with
a maturity value of $9,030,000 were purchased for $8,844,400. At September 30, 2023, these securities were recorded at a market value
of $8,955,300.
Note E — Prepaid Expenses
Prepaid expenses at September
30, 2023 and December 31, 2022 include:
| |
September 30, 2023 | | |
December 31, 2022 | |
Prepaid insurance | |
$ | 917,807 | | |
$ | 29,359 | |
Prepaid rent | |
| - | | |
| 16,200 | |
Prepaid other | |
| 53,432 | | |
| 17,365 | |
| |
$ | 971,239 | | |
$ | 62,924 | |
Note F — Other Current Assets
Other current assets at September
30, 2023 and December 31, 2022 include:
| |
September 30, 2023 | | |
December 31, 2022 | |
Tax credit receivable | |
$ | 8,785 | | |
$ | 15,903 | |
Receivable with related party | |
| - | | |
| 46,401 | |
State income tax receivable | |
| 5,581 | | |
| 13,231 | |
| |
$ | 14,366 | | |
$ | 75,535 | |
INTENSITY THERAPEUTICS,
INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note G — Other Assets
Other assets at September
30, 2023 and December 31, 2022 include:
| |
September 30, 2023 | | |
December 31, 2022 | |
Deposit with vendor | |
$ | - | | |
$ | 150,000 | |
Deposits with landlords | |
| 28,438 | | |
| 17,738 | |
| |
$ | 28,438 | | |
$ | 167,738 | |
Note H — Accrued Expenses
Accrued expenses at September
30, 2023 and December 31, 2022 include:
| |
September 30, 2023 | | |
December 31, 2022 | |
Accrued vacation, wages, and related payroll taxes | |
$ | - | | |
$ | 328,527 | |
Patient costs incurred but not yet invoiced | |
| 340,639 | | |
| 1,392,604 | |
Accrued other | |
| 14,367 | | |
| 2,269 | |
| |
$ | 355,006 | | |
$ | 1,723,400 | |
Note I — Convertible Notes
Prior to the June 29, 2023 IPO, the Company entered
into a series of interest bearing convertible notes described below. On June 29, 2023, all notes converted to shares following the pricing
of the IPO.
On September 20, 2021, the
Company entered into a convertible debt agreement (the “2021 Convertible Note”) with a shareholder for aggregate principal
of $2,000,000 due October 1, 2025, as amended on November 29, 2022, with the following conversion terms. The outstanding principal balance
together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO in excess of
$7,000,000 gross proceeds, (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities,
(iii) Non-IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of October 1, 2025. If
an IPO, sale event or Non-IPO financing occurred between September 20, 2021 through September 19, 2022 a conversion price discount of
25% would be assessed, if between September 20, 2022 through March 19, 2023 a conversion price discount of 30% would be assessed, if between
March 20, 2023 through October 1, 2025 a conversion price discount of 35% would be assessed. Otherwise at the maturity date a conversion
price of $11.50 per share would be assessed. The 2021 Convertible Note accrues interest at 3% per annum, convertible to shares as previously
described herein. On November 29, 2022 this agreement was amended so that the interest rate changes to 6% per annum after October 1, 2023.
The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary
bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e)
defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be
immediately due and payable.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note I — Convertible Notes (continued)
On November 21, 2022, the
Company entered into two convertible debt agreements (the “November 21, 2022 Convertible Notes”) with shareholders for $250,000
and $500,000. The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted
upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of
the company’s assets or a majority of its equity securities, (iii) Non-IPO financing by selling preferred stock in an equity offering
other than an IPO or (iv) maturity date of November 21, 2024. If an IPO, sale event or Non-IPO financing occurred prior to November 21,
2024 a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would
be assessed. The November 21, 2022 Convertible Notes accrue interest at 10% per annum, convertible to shares as previously described herein.
The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary
bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e)
defaults under other indebtedness. Under these occurrences, the holders may declare all outstanding principal and interest payable to
be immediately due and payable.
On November 29, 2022, the
Company entered into a convertible debt agreement (the “November 29, 2022 Convertible Note”) for $1,500,000 with a holder.
The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the
earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of the company’s
assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an
IPO or (iv) maturity date of October 1, 2025. If an IPO, sale event or Non-IPO financing occurred prior to October 1, 2025 a conversion
price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. The
November 29, 2022 Convertible Note accrues interest at 10% per annum, convertible to shares as previously described herein. The occurrence
of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy
or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under
other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due
and payable.
On March 16, 2023, the Company
entered into a convertible debt agreement (the “March 16, 2023 Convertible Note”) for $50,000 with a holder. On March 30,
2023 the Company entered into a convertible note debt agreement (the “March 30, 2023 Convertible Note”) for $155,000 with
a holder. The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted
upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s
assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an
IPO or (iv) maturity date of March 16, 2026 for the March 16, 2023 Convertible Note and March 30, 2026 for the March 30, 2023 Convertible
Note. If an IPO, sale event or Non-IPO financing occurred prior to March 16, 2026 for the March 16, 2023 Convertible Note or prior to
March 30, 2026 for the March 30, 2023 Convertible Note, a conversion price discount of 30% would be assessed. Otherwise at the maturity
date a conversion price of $11.50 per share would be assessed. These notes accrue interest at 10% per annum, convertible to shares as
previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any
principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements
in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal
and interest payable to be immediately due and payable.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note I — Convertible Notes (continued)
On April 1, 2023, the Company
entered into a convertible debt agreement (the “April 1, 2023 Convertible Note”) for $12,552 with our landlord in exchange
for services. The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted
upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s
assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an
IPO or (iv) maturity date of April 1, 2026. If an IPO, sale event or Non-IPO financing occurred prior to April 1, 2026, a conversion price
discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. This note
accrues interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would
constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c)
involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under
these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable.
On May 11, 2023, the Company
entered into a convertible debt agreement (the “May 11, 2023 Convertible Note”) for $25,000 with a holder. The outstanding
principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i)
an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority
of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity
date of May 11, 2026. If an IPO, sale event or Non-IPO financing occurred prior to May 11, 2026, a conversion price discount of 30% would
be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. These note accrues interest at 10%
per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default:
a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency
proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare
all outstanding principal and interest payable to be immediately due and payable.
A loss was recorded to account for the discount
given to convertible noteholders as provided by their convertible note agreements. Upon the settlement of the notes, a loss of $2,261,581
was recorded on the Statement of Operations for the nine months ended September 30, 2023 for the discount given to the convertible debt
holders.
The balance at December
31, 2022 consists of:
| |
Principal | | |
Accrued Interest | | |
Total | |
Convertible note dated September 20, 2021 | |
$ | 2,000,000 | | |
$ | 76,767 | | |
$ | 2,076,767 | |
Convertible notes dated November 21, 2022 | |
| 750,000 | | |
| 8,219 | | |
| 758,219 | |
Convertible note dated November 29, 2022 | |
| 1,500,000 | | |
| 13,562 | | |
| 1,513,562 | |
| |
$ | 4,250,000 | | |
$ | 98,548 | | |
$ | 4,348,548 | |
There was no balance in Convertible
notes as of September 30, 2023 since all principal and accrued interest of $4,492,552 and $244,447, respectively was converted into 1,399,716
shares of common stock on June 29, 2023.
At December 31, 2022, the
Company classified the convertible notes as a current liability since the Company anticipated that these notes will automatically convert
into shares of common stock within one year of the balance sheet date. The unamortized discount was amortized over the life of the convertible
notes. The unamortized balance at the time of the conversion into shares of common stock of approximately $117,700 is included in interest
expense in the Statement of Operations.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note J — Stockholders’ Equity
On June 29, 2023, as described
in Note A, the Company priced its IPO, issuing 3,900,000 shares of common stock. Pursuant to the IPO, all of the Company’s preferred
stock was converted into common stock at conversion prices that reflected the Reverse Stock Split effective June 29, 2023. All convertible
notes and related accrued interest were converted into 1,399,716 shares of common stock, as described in Note I and the Company recorded
a non-operating loss on debt extinguishment on the Statement of Operations for $2,261,581 which is equal to the discount on the IPO price
that was specified in the convertible note agreements. As the IPO price was less than the original issue price per share of the Series
B and Series C preferred stock, each of these series received a conversion price adjustment pursuant to their original terms. Upon conversion
of the preferred stock, the Company issued an additional 100,189 shares of common stock pursuant to Series B conversion price adjustment
and an additional 164,518 shares of common stock pursuant to the Series C conversion price adjustment. The additional shares have been
recorded as a deemed dividend on the Statement of Operations and Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders’
Equity (Deficiency).
On July 7, 2023, the Company
sold the full overallotment of the IPO shares and issued 585,000 shares of common stock at the IPO price of $5.00 per share.
The sixth amended and restated
Certificate of Incorporation, which was approved by the Company’s stockholders on November 23, 2021, increased the number of authorized
shares from 50,000,000 to 135,000,000 upon the completion of the IPO.
Note K — Common Stock Warrants
The following table summarizes
information about common stock warrants at September 30, 2023 and 2022:
| |
Number of Shares
Underlying
Warrants | | |
Weighted
Average
Exercise Price | |
Outstanding January 1, 2022 | |
| 323,250 | | |
$ | 6.01 | |
Issued | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | |
Forfeited | |
| - | | |
| - | |
Outstanding March 31, 2022 | |
| 323,250 | | |
| 6.01 | |
Issued | |
| - | | |
| | |
Exercised | |
| - | | |
| | |
Forfeited | |
| - | | |
| | |
Outstanding June 30, 2022 | |
| 323,250 | | |
| 6.01 | |
Issued | |
| - | | |
| | |
Exercised | |
| - | | |
| | |
Forfeited | |
| - | | |
| | |
Outstanding September 30, 2022 | |
| 323,250 | | |
$ | 6.01 | |
| |
| | | |
| | |
Outstanding January 1, 2023 | |
| 357,750 | | |
$ | 6.00 | |
Issued | |
| 30,000 | | |
| 12.50 | |
Exercised | |
| - | | |
| | |
Forfeited | |
| - | | |
| | |
Outstanding March 31, 2023 | |
| 387,750 | | |
| 6.51 | |
Issued | |
| 273,000 | | |
| 6.00 | |
Exercised | |
| - | | |
| | |
Forfeited | |
| - | | |
| | |
Outstanding June 30, 2023 | |
| 660,750 | | |
| 6.30 | |
Issued | |
| 40,950 | | |
| 6.00 | |
Exercised | |
| (12,500 | ) | |
| 2.00 | |
Forfeited | |
| - | | |
| | |
Outstanding September 30, 2023 | |
| 689,200 | | |
$ | 6.36 | |
| |
| | | |
| | |
Exercisable September 30, 2023 | |
| 659,450 | | |
$ | 6.21 | |
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note K — Common Stock Warrants (continued)
The following table summarizes
the assumptions used to estimate the fair value of 30,000 stock warrants granted on January 1, 2023 at the date of grant:
Stock price | |
$ | 4.50 | |
Exercise price | |
$ | 6.25 | |
Expected volatility | |
| 103.85 | % |
Risk free interest rates | |
| 3.59 | % |
Term | |
| 3 years | |
30,000 warrants were granted
on January 1, 2023 to two holders of convertible notes. These warrants were exercisable upon issuance and expire in three years. The value
of the warrants is $159,262. The value of the warrants is recorded as a discount to the convertible notes and was being amortized over
the life of the convertible notes. The amortization appears on the Statement of Operations as interest expense.
The following table summarizes
the assumptions used to estimate the fair value of stock warrants committed by the Company on June 29 and July 7, 2023 as part of the
IPO and sale of the IPO overallotment:
Stock price | |
$ | 5.00 | |
Exercise price | |
$ | 6.00 | |
Expected volatility | |
| 101.46 | % |
Risk free interest rates | |
| 3.97 | % |
Term | |
| 5 years | |
273,000 warrants were granted
to the underwriters of the IPO for the sale of the IPO base shares. The value of these warrants is approximately $1,017,000. 40,950 warrants
were granted to the underwriters for the sale of the overallotment shares. The value of these warrants is approximately $153,000. All
of these warrants are recorded as both an increase and decrease to Additional Paid in Capital on the Balance Sheet since they are costs
related to the issuance of the shares of common stock. These warrants are exercisable beginning on January 5, 2024 and expire January
5, 2029. There was no stock compensation expense recorded on these warrants.
The Company recognized stock-based
compensation expense related to warrants in its condensed Statements of Operations as follows (approximately):
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Research and Development | |
$ | 67,000 | | |
$ | 4,000 | | |
$ | 203,000 | | |
$ | 11,000 | |
General and Administrative | |
| 4,000 | | |
| - | | |
| 11,000 | | |
| 100,000 | |
Total | |
$ | 71,000 | | |
$ | 4,000 | | |
$ | 214,000 | | |
$ | 111,000 | |
At September 30, 2023, total
unrecognized compensation cost related to warrants was approximately $164,000 and is expected to be recognized over the remaining weighted
average service period of 1.9 years.
The aggregate intrinsic value
of outstanding warrants is calculated as the difference between the exercise price of the stock warrants and the fair value of the Company’s
common stock for those stock warrants that had exercise prices lower than the fair value of the Company’s common stock. The aggregate
intrinsic value of outstanding warrants was approximately $67,000 at September 30, 2023.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note L — Stock Based Compensation
The Company had a stock option
plan, the 2013 Plan, which is administered by our Compensation Committee. Under the 2013 Plan, stock options to purchase a total of 4,500,000
shares of common stock could be granted to eligible employees, officers, directors and consultants of the Company.
In 2020, the Company amended
its 2013 Stock Option Plan (the “2013 Plan”) to increase the number of authorized shares available under the 2013 Plan from
1,800,000 to 4,500,000. On November 12, 2021, the Company adopted the 2021 Stock Incentive Plan (the “2021 Plan”) authorizing
the granting of equity awards for the issuance of up to 3,000,000 shares of common stock. Prior to the adoption of the 2021 Plan, there
were 2,677,500 shares available under the 2013 Plan. However, upon adoption of the 2021 Plan, no more shares would be issued under the
2013 Plan. Starting on January 1, 2022, the shares authorized under the 2021 Plan shall have an annual increase of the lessor of (a)
3.5% of the aggregate number of shares of Common Stock outstanding on the final day of the preceding calendar year, or (b) such smaller
amount as determined by the Board. On January 1, 2023, an additional 238,700 shares were authorized under the 2021 Plan.
The following table summarizes
information about common stock options at September 30, 2023 and 2022:
|
|
Number of Shares
Underlying
Options |
|
|
Weighted
Average
Exercise Price |
|
|
|
|
|
|
|
|
Outstanding at January 1, 2022 |
|
|
911,250 |
|
|
$ |
8.57 |
|
Issued |
|
|
- |
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
|
|
Forfeited |
|
|
- |
|
|
|
|
|
Outstanding March 31, 2022 |
|
|
911,250 |
|
|
|
8.57 |
|
Issued |
|
|
- |
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
|
|
Forfeited |
|
|
- |
|
|
|
|
|
Outstanding June 30, 2022 |
|
|
911,250 |
|
|
|
8.57 |
|
Issued |
|
|
- |
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
|
|
Forfeited |
|
|
(60,000 |
) |
|
|
11.50 |
|
Outstanding September 30, 2022 |
|
|
851,250 |
|
|
$ |
8.36 |
|
|
|
|
|
|
|
|
|
|
Outstanding January 1, 2023 |
|
|
1,044,250 |
|
|
$ |
8.48 |
|
Issued |
|
|
- |
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
|
|
Forfeited |
|
|
- |
|
|
|
|
|
Outstanding March 31, 2023 |
|
|
1,044,250 |
|
|
|
8.48 |
|
Issued |
|
|
- |
|
|
|
|
|
Exercised |
|
|
- |
|
|
|
|
|
Forfeited |
|
|
- |
|
|
|
|
|
Outstanding June 30, 2023 |
|
|
1,044,250 |
|
|
|
8.48 |
|
Issued |
|
|
50,000 |
|
|
|
6.43 |
|
Exercised |
|
|
(12,500 |
) |
|
|
2.00 |
|
Forfeited |
|
|
- |
|
|
|
|
|
Outstanding September 30, 2023 |
|
|
1,081,750 |
|
|
$ |
8.46 |
|
|
|
|
|
|
|
|
|
|
Exercisable September 30, 2023 |
|
|
801,750 |
|
|
$ |
8.10 |
|
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note L — Stock Based Compensation (continued)
The aggregate intrinsic value
of outstanding options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s
common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate
intrinsic value of options outstanding was approximately $85,000 at September 30, 2023.
Employee option vesting is
based on the employee’s continued service with the Company.
The 2013 Plan and the 2021
Plan provide an immediate vesting of outstanding options in the event of a change of control, such as an acquisition, notwithstanding
any other provision of the 2013 Plan or 2021 Plan.
The following table summarizes
the assumptions used to estimate the fair value of stock options issued on July 19, 2023:
Stock price | |
$ | 6.43 | |
Exercise price | |
$ | 6.43 | |
Expected volatility | |
| 99.74 | % |
Risk free interest rates | |
| 3.87 | % |
Expected term | |
| 3 years | |
At September 30, 2023, total
unrecognized compensation cost related to options was approximately $1,466,000 and is expected to be recognized over the remaining weighted
average service period of 1.6 years.
The Company recorded stock-based
compensation related to stock options in its condensed Statements of Operations as follows (approximately):
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Research and Development | |
$ | 119,000 | | |
$ | (21,000 | ) | |
$ | 448,000 | | |
$ | 286,000 | |
General and Administrative | |
| 161,000 | | |
| 58,000 | | |
| 313,000 | | |
| 144,000 | |
Total | |
$ | 280,000 | | |
$ | 37,000 | | |
$ | 761,000 | | |
$ | 430,000 | |
All options expire ten years
from date of grant. Options outstanding begin to expire in August 2024. Options that were granted to employees and consultants have vesting
periods that vary by award to recipient and range from immediate vesting to a period of up to 4 years.
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note M — Leases
In January 2017, the Company
entered into a lease for 2,534 square feet of office space in Westport, Connecticut, the “Westport Lease”). The lease commenced
in May 2017. The initial lease term was two years. In November 2018, the Company exercised the option to extend the lease for an additional
three years.
In July 2020, the Company
amended the Westport Lease to increase office space by an additional 1,653 square feet in the same building. The amended lease that includes
the space included in the original lease had monthly rent as follows:
Year 1 (October 2020 through September 2021) |
$15,502 per month |
($44.43 per square foot) |
Year 2 (October 2021 through September 2022) |
$15,851 per month |
($45.43 per square foot) |
Year 3 (October 2022 through September 2023) |
$16,200 per month |
($46.43 per square foot) |
The Company had an option
to extend this amended lease for an additional 3 years at the following amounts:
Year 4: (October 2023 through September 2024) |
$16,338 per month |
($46.83 per square foot) |
Year 5: (October 2024 through September 2025) |
$16,476 per month |
($47.22 per square foot) |
Year 6: (October 2025 through September 2026) |
$16,825 per month |
($48.22 per square foot) |
The Company had until March
31, 2023 to exercise this option to extend. On February 27, 2023, the Company informed the landlord that it will not exercise its option
to extend the amended lease. On March 27, 2023, the Company modified the lease to reduce the office space as of April 30, 2023 and to
further reduce the office space as of May 31, 2023. These two modifications reduced the operating lease asset and liability. The amended
lease was set to expire on September 30, 2023. On April 17, 2023 another modification was made to the lease that terminated the lease
as of June 30, 2023.
The Company also paid a pro-rata
share of operating expenses and real estate taxes. For the Westport Lease, the following variables were used to determine the right-of-use
asset and the operating lease liabilities as of commencement date: Weighted average remaining lease term 1.00 years and Weighted average
operating lease discount rate 3.92%.
On July 7, 2023 the Company
signed a 5.5 year lease for 2,686 square feet of office space in Shelton, Connecticut, (the “Shelton Lease”.) The initial
monthly base rent payments are zero for the first six months, $2,910 for each of the next six months, and gradually increase to $3,275
per month for the last twelve months. The lease commencement date was September 1, 2023. The Company also pays a pro-rata share of common
area maintenance, real estate taxes, and insurances which are treated as non-lease components and recorded as variable facilities costs
on a monthly basis. The Company has a one-time option to cancel the Shelton Lease after 36 months if it provides written notice before
the end of month 30. An additional $46,679 would be due at the end of month 36 if the Company exercises this option. This option is not
reasonably certain to occur.
The Shelton Lease uses a
discount rate of 6.39% and a weighted average remaining term of 5 years 5 months as of September 30, 2023. Rent expense for the nine months
ended September 30, 2023 was $54,547 of which $2,842 pertains to the Shelton Lease for the month of September 2023.
The following table summarizes
the balance sheet classification of the operating lease asset and related lease liabilities at September 30, 2023 for the Shelton Lease
and at December 31, 2022 for the Westport Lease:
| |
September 30,
2023 | | |
December 31,
2022 | |
| |
| | |
| |
Operating lease right-of-use assets | |
$ | 152,605 | | |
$ | 139,089 | |
| |
| | | |
| | |
Current portion of operating lease liabilities | |
$ | 10,556 | | |
$ | 143,221 | |
Long-term operating lease liabilities | |
| 144,891 | | |
| - | |
| |
$ | 155,447 | | |
$ | 143,221 | |
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
September 30, 2023
Note N — Other Uncertainties
The Company holds one of
its patents in Russia. The payment for this patent is paid until September 15, 2024. If subsequent payments to Russia are restricted,
the Company may lose this patent in Russia. The Company has no other significant business activities in Belarus, Russia or the Ukraine.
The Company also holds a patent in Israel which is currently involved in military action.
Note O — Related Parties
The liabilities section of
the September 30, 2023 and December 31, 2022 balance sheet shows a $36,000 deposit related to a Provider Service Agreement (“PSA”)
with a minority stockholder. This account is entitled “Related party deposit” on the balance sheet. This deposit will be returned
to the minority stockholder at the end of the PSA once all charges have been settled. At September 30, 2023 and December 31, 2022, the
Company had a receivable of approximately none and $46,400, respectively, related to this agreement. This receivable is included in “Other
current assets” on the balance sheet.
In February 2022, a minority
stockholder became a consultant to the Company. Services provided include acting as the Company’s Chief Medical Officer. The Company
has accrued approximately none and $95,900 at September 30, 2023 and December 31, 2022, respectively. This liability is included in accounts
payable. Expenses related to this consulting agreement were approximately $6,200 and $80,900 for the nine months ended September 30, 2023
and 2022, respectively and approximately $2,200 and $15,000 for the three months ended September 30, 2023 and 2022, respectively.
Sublease income from the
related party was approximately $23,000 and $50,600 for the nine months ended September 30, 2023 and 2022 and none and approximately $16,900
for the three months ended September 30, 2023 and 2022. April 2023 was the last month for the sublease income. Sublease income is recorded
as a reduction of general and administrative expenses in the Statement of Operations.
Note P — Income Taxes
The Company recorded Federal
research and development credits, of approximately $18,300 and $47,700 for the nine months ended September 30, 2023 and 2022, respectively.
These amounts are included in Other Income in the Statements of Operations. Other current assets include a tax credit that is the Federal
refundable research and development tax credit.
At September 30, 2023, the
Company generated Connecticut and Federal net operating loss carryforwards of approximately $30.3 million. For the Federal net operating
loss carryforwards, approximately $7.0 million expire at various dates beginning in 2033. Under the Tax Cuts and Job Act passed on December
22, 2017, corporate net operating losses generated beginning in 2018 cannot be carried back but are carried forward indefinitely. The
Internal Revenue Code (the “IRC”) contains limitations on the use of net operating loss carryforwards after the occurrence
of substantial ownership changes as defined by IRC Section 382. Utilization of such operating loss carryforwards may be limited if such
capital raises are determined to be a change in ownership under IRC Section 382.
At September 30, 2023, aside
from the Federal research and development tax credits used to offset Social Security taxes, the Company had Federal General Business Credit
carryforwards of approximately $439,400 which are available to offset future taxable income expiring at various times beginning in 2033.
At September 30, 2023, the
Company has Connecticut research and development tax credit carryforwards of approximately $196,600 which are available to offset future
Connecticut taxable income.
Note Q — Retirement Plan – Defined Contribution
The Company maintains a defined
contribution plan for all employees age 21 and older who have completed one month of service. This 401K plan began for payrolls after
July 1, 2017. The Company makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s
eligible earnings. The Company match is vested after one year of service. Retirement expense for this plan was approximately $14,700 and
$29,300 for the nine months ended September 30, 2023 and 2022, respectively and approximately $4,800 and $6,000 for the three months ended
September 30, 2023 and 2022, respectively.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations.
FORWARD-LOOKING STATEMENTS
This Quarterly Report
on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial
or operating performance and may include statements concerning, among other things, our business strategy (including anticipated trends
and developments in, and management plans for, our business and the markets in which we operate), financial results, operations, and the
markets and communities in which we, our clients, and partners operate, results of operations, revenues, operating expenses, and capital
expenditures, sales and marketing initiatives and competition. In some cases, you can identify forward-looking statements because they
contain words such as “may,” “might,” “will,” “should,” “expects,” “plans,”
“anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “suggests,” “potential” or “continue”
or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These
statements are not guarantees of future performance; they reflect our current views with respect to future events and are based on assumptions
and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from expectations or results projected or implied by forward-looking statements.
We discuss many of these
risks in our Final Prospectus on Form 424(b)(4) dated June 29, 2023, in greater detail under the heading “Risk Factors” and
in other filings we make from time to time with the Securities and Exchange Commission (“SEC”). Also, these forward-looking
statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q, which are inherently subject
to change and involve risks and uncertainties. Unless required by federal securities laws, we assume no obligation to update any of these
forward-looking statements, or to update the reasons actual results could differ materially from those anticipated, to reflect circumstances
or events that occur after the statements are made. Given these uncertainties, you should not place undue reliance on these forward-looking
statements. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number
of factors. Such factors include, but are not limited to, the following:
|
● |
the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs; |
|
● |
our need to raise additional funding before we can expect to generate any revenues from product sales; |
|
● |
our plans to develop and commercialize our product candidates; |
|
● |
the timing or likelihood of regulatory filings and approvals; |
|
● |
the ability of our research to generate and advance additional product candidates; |
|
● |
the implementation of our business model, strategic plans for our business, product candidates and technology; |
|
● |
our commercialization, marketing and manufacturing capabilities and strategy; |
|
● |
the rate and degree of market acceptance and clinical utility of our system; |
|
● |
our competitive position; |
|
● |
our intellectual property position; |
|
● |
developments and projections relating to our competitors and our industry; |
|
● |
our ability to maintain and establish collaborations or obtain additional funding; and |
|
● |
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. |
You should read this Quarterly
Report on Form 10-Q and the documents that we reference in this report and have filed with the SEC, including our Final Prospectus on
Form 424(b)(4) dated June 29, 2023, completely and with the understanding that our actual future results may be materially different from
what we expect. We qualify all of our forward-looking statements by these cautionary statements.
References to “Notes”
are notes included in our unaudited Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Unless otherwise indicated,
the terms “Intensity,” “Company,” “we,” “us,” or “our” refer to Intensity
Therapeutics, Inc.
Overview
Intensity Therapeutics, Inc.
is a clinical-stage biotechnology company committed to applying scientific leadership in the field of localized cancer reduction leading
to anti-cancer immune activation. Our approach involves the direct injection into tumors of a unique product created from our DfuseRx℠
discovery platform.
The concept of intratumoral
treatment (IT) has been an objective of clinicians since the first discovery of chemotherapeutic agents. Keeping the drug in the tumor
and sparing the body of toxicity. The challenge with IT treatment approaches is that a tumor’s lipophilic, high fat and pressurized
microenvironment is incompatible with and does not absorb water-based products. We believe that intratumoral drug delivery is a chemistry
challenge and that prior or current IT treatments have formulated their product without consideration of the incompatibility of water
and tumors. Another issue with IT or local delivery has been that metastatic cancer is a whole body disease. Local treatments need a systemic
component to be effective for a survival benefit. Accordingly, there remains a continued unmet need for the development of direct IT therapies
for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. We believe we have created
such a product candidate with the necessary chemistry to overcome this local delivery challenge and a mechanism of action that induces
a systemic effect. Clinical and nonclinical evidence shows that our drug candidate’s mechanism of tumor killing also leads to immune
activation in certain cancers.
Our platform creates patented
anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct
components: one part is soluble in water and the other is soluble in fat or oils. When certain amphiphilic compounds are mixed with therapeutic
agents, such as chemotherapies, the agents can also become soluble in both fat and water. Our product candidates include novel formulations
consisting of potent anti-cancer drugs mixed together with these amphiphilic agents.
Our lead product candidate,
INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule
(SHAO) — all in one vial. The anti-cancer agents, cisplatin and vinblastine sulfate, used in our product candidate are both generic
and are available to purchase in bulk supply commercially. In 2017, we initiated a Phase 1/2 dose escalation study using INT230-6 in the
United States under an investigational new drug application (“IND”) authorized by the FDA and in Canada following receipt
of a no objection letter from Health Canada. The study, IT-01, explored the safety and efficacy of INT230-6 in patients with refractory
or metastatic cancers. We completed enrollment of study IT-01 in June 2022 and locked the IT-01 database in February 2023 and finalized
the clinical study report in September 2023.
The
IT-01 trial dosed 110 patients. This clinical trial used our lead product candidate INT230-6 alone; in combination with
Merck’s Keytruda® (pembrolizumab) for patients with advanced solid malignancies including pancreatic, bile duct, squamous cell,
and non-MSI high colon cancers; and in combination with Bristol Myers Squibb’s Yervoy® (ipilimumab) for patients with breast
cancer, liver cancer, and advanced sarcoma. In the third quarter of 2023 we completed the clinical study reports (CSR) for the IT-01 trial.
We expect to deliver the reports and other information to our partners in the fourth quarter of 2023.
Our second clinical trial
(the INVINCIBLE Study or IT-02) tested INT230-6 in early stage breast cancer for patients not suitable for presurgical chemotherapy.
The study enrolled 91 subjects; enrollment is now complete. This clinical trial was a Phase 2 randomized, window of opportunity for
patients who were ineligible or chose not to have presurgical chemotherapy. The key endpoint was whether INT230-6 could reduce patient’s
cancer by 50% to 100% defined as a major pathological response compared to no treatment (the current standard of care) or a saline injection
and stimulate a systemic anti-cancer immune response prior to surgery. Substantial reduction of cancer presurgically in aggressive forms
of cancer has been shown to correlate with delaying disease recurrence. Other endpoints of the INVINCIBLE study were to understand the
percentage of necrosis that can be achieved in tumors especially tumors larger than 2 cm in longest diameter and whether either a local
or whole body anti-cancer immune response could be induced. In the third quarter of 2023 we finalized the statistical analysis plan and
the design of the tables listings and figures.
On
September 7, 2023, the Company announced that the FDA’s Office
of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma to the three active
moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (((2-hydroxybenzoyl) amino)
octanoate). The Orphan Drug Designation qualifies the Company for incentives including tax credits for qualified clinical trials,
exemption from user fees and potentially seven years of marketing exclusivity for products containing these three key components
should the Company gain approval of INT230-6 for treatment of soft tissue sarcoma.
Phase 3 Sarcoma Study
The Company intends to test
INT230-6 as a treatment in advance soft tissue sarcoma with an endpoint of overall survival. In the third quarter of 2023, the Company
continued to work on the protocol for Study IT-03 which treats soft tissue sarcoma. To achieve this objective immediately following the
close of the IPO we reserved a slot with our drug product manufacturing vendor to produce a new batch of INT230-6 in the fourth quarter
of 2023 that would be suitable for phase 3 clinical use. For phase 3 development and validation of new assays for determining vinblastine
and SHAO concentrations in our drug product was required. The assay for cisplatin was already phase 3 ready. The new assays have been
developed. we anticipate validation of the methods to begin and complete in the fourth quarter. In our meeting with FDA held in October
of 2021, the Agency requested we schedule a Chemical Manufacturing and Controls (CMC) meeting to discuss the issues needed for phase 3
and product registration. We submitted our CMC questions in Q3 to the Agency. The FDA granted us a meeting that is scheduled to occur
in the fourth quarter of 2023. In the third quarter of 2023 we drafted several of the required documents necessary for commencing the
soft tissue sarcoma phase 3 study. Our intent is to submit an IND to FDA with the phase 3 protocol in the fourth quarter of 2023.
Phase 2/3 Program in Presurgical
Breast Cancer
Based on the data generated
and presented to date, we are working to develop a phase 2/3 study protocol in presurgical (neoadjuvant) breast cancer. The study will
test INT230-6 in combination with the standard of care (SOC) treatment (chemotherapy/immunotherapy) compared to SOC alone in women with
triple negative breast cancer. The clinical materials being manufactured in the fourth quarter of 2023 for the sarcoma study will also
be used in the breast cancer study. The endpoint for the phase 2 portion of the trial will a change in pathological complete response
rate for the combination compared to the SOC alone. That data will allow for sizing of the phase 3 program.
Since our inception in 2012,
our operations have included business planning, hiring personnel, raising capital, building our intellectual property portfolio, and performing
both research and development on our product candidates. We have incurred net losses since inception and expect to incur net losses in
the future as we continue our research and development activities. To date, we have funded our operations primarily through approximately
$54.5 million in cash received from the net proceeds of sales of our common stock, preferred stock and convertible notes. As of September
30, 2023, we had approximately $6.7 million of cash and cash equivalents plus approximately $9.0 million in investments in U.S. Treasury
bills. Since our inception, we have incurred significant operating losses. We incurred net losses of $2.3 million and $1.8 million
for the three months ended September 30, 2023 and 2022, respectively, and losses of $7.4 million and $6.1 million for the nine months
ended September 30, 2023 and 2022, respectively. As of September 30, 2023, we had an accumulated deficit of approximately $47.3 million.
We expect to incur significant expenses and operating losses for the next several years. See “Funding Requirements” below.
We expect our expenses to
increase as we continue to:
|
● |
Initiate Phase 3 programs in sarcoma and/or breast cancer; |
|
● |
Complete our current Phase 2 programs; |
|
● |
Advance our preclinical research and bring new product candidates into clinical development; |
|
● |
Incur manufacturing costs for additional GMP batches of our product candidates and enhancer molecules; |
|
● |
Seek regulatory approvals for any of our product candidates that successfully complete clinical trials; |
|
● |
Hire additional personnel; |
|
● |
Expand our operational, financial, and management systems; |
|
● |
Invest in measures to protect our existing and new intellectual property; and |
|
● |
Establish a sales, marketing, medical affairs, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize. |
Our ability to ultimately
generate revenue to achieve profitability will depend heavily on the development, approval, and subsequent commercialization of our product
candidates. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and be forced to reduce or terminate our operations.
As a result, we will need
substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate
significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financing, or other
capital sources, which may include collaborations with other companies or other strategic transactions. We may not be able to raise additional
funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter
into such agreements as and when needed, we would have to significantly delay, reduce, or eliminate the development and commercialization
of one or more of our product candidates.
Components of Results of Operations
Revenue
To date, we have not generated
any revenue from product sales and we do not expect any revenue from the sale of product in the foreseeable future. We have not generated
any revenue from licensing of our technology or product candidates yet either. If our development efforts for any of our product candidates
are successful and result in regulatory approval, then we may generate revenue in the future from product sales or licensing. We cannot
predict if, when, or to what extent we will generate revenue from the commercialization, licensing or sale of any of our product candidates.
We may never succeed in obtaining regulatory approval for any of our product candidates.
Research and Development Costs
Salaries and Payroll Taxes
Salaries and payroll taxes
include Company employees involved in our pre-clinical research and clinical trials. This includes medical officers, project management,
manufacturing staff and research scientists. The payroll taxes include all government required payments such as social security and unemployment
taxes.
Benefits
We offer a partially funded
health insurance and dental insurance plan. We maintain a defined contribution plan for all employees age 21 and older who have completed
one year of service. This 401K plan makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s
eligible earnings.
Clinical Trial and Other Costs
Research costs include:
|
● |
Manufacture of new enhancer compounds, |
|
● |
Manufacture and labelling of GMP product candidate |
|
● |
Product candidate stability testing of GMP batches |
|
● |
Costs due to clinical trials for patient care |
|
● |
Other clinical trial costs such as shipping, storage, and analytical testing |
| ● | Scientific consulting costs related to non-employees involved
in research. This category includes: statistical analysis, clinical trial operations, development of product manufacturing techniques,
and internet research related to oncology and chemistry issues that may impact our preclinical or clinical research. |
Stock-Based Compensation
Stock-based compensation
is the expense related to stock options granted to our employees and board members and warrants granted to our independent consultants
who work in the research aspects.
General and Administrative Costs
Salaries and Payroll Taxes
Salaries and payroll taxes
include Company employees who are involved in fund raising, management, and our financial administration. The payroll taxes include all
government required payments such as social security and unemployment taxes.
Benefits
We offer a partially funded
health insurance and dental insurance plan. We maintain a defined contribution plan for all employees age 21 and older who have completed
one year of service. This 401K plan makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s
eligible earnings.
Legal
Legal costs relate primarily
to our corporate administration. All legal costs relate to expenses for outside law firms.
Patent and Trademark
Patent and Trademark are
the legal costs and filing costs to establish and maintain patents in 38 countries.
Insurance
Insurance includes: directors
and officers insurance, workers compensation insurance, product liability insurance, business insurance, employee and cyber liability
insurance.
Facilities and Rent
Facilities and rent through
June 30, 2023 is the cost of maintaining our office facility in Westport, Connecticut. The three months ended September 30, 2023 includes
some minor costs related to temporary storage of furniture and equipment as we transitioned into our new office space.
In July 2023, we signed a
lease to move into 2,686 square feet of office space at 1 Enterprise Drive, Suite 430, Shelton, Connecticut to improve recruiting of staff
and to reduce costs. The three months ended September 30, 2023 includes the cost of renting and maintaining this office space.
The commencement date of
the Shelton Lease is September 1, 2023 and rent for September 2023 was $2,842. The initial payments for base rent is zero for the first
six months, $2,910 for each of the next six months, and gradually increase to $3,275 per month for the final months of the lease. The
Company has an option to cancel this lease after 36 months.
Investor Relations
Investor relations are costs
paid to outside consultants to develop the materials to present to current and prospective investors, and to arrange meetings with potential
investors.
Accounting Services
Accounting services include
the cost of our independent auditors for our annual audit, quarterly reviews, and services related to the filing forms with the Securities
and Exchange Commission. Accounting services also includes costs related to the preparation of income tax returns, and the cost of maintaining
our accounting system. Accounting services on our IPO were not included in this category. The costs related to the IPO were recorded as
a reduction of proceeds of the offering and are part of additional paid-in capital on the September 30, 2023 balance sheet.
Consulting Services
Consulting Services are services
provided by non-employees for general and administrative tasks. This includes human resources, finance, board compensation, and internet
support.
Other
Other general and administrative
costs include such items as office supplies, computer related costs, public relations costs, recruiting costs and conferences.
Stock-Based Compensation
Stock-based compensation
is the expense related to stock options granted to our employees and board members and warrants granted to our independent consultants
who work in the general and administrative aspects.
Other income and expenses
We earned interest income
on our cash balances and investments in U.S. Treasury bills.
We incurred interest expense
on our convertible notes through June 29, 2023. Accrued interest was converted into common stock upon commencement of our IPO.
We accumulated federal research
and development tax credits in prior tax years that are recoverable through a refund of Social Security taxes paid in current fiscal periods.
Results of Operations
The following tables summarize
our results of operations for the three months ended September 30, 2023 and 2022:
| |
Three Months Ended September 30, | | |
Increase | |
| |
2023 | | |
2022 | | |
(Decrease) | |
Operating expenses: | |
| | |
| | |
| |
Research and development costs | |
$ | 1,351,766 | | |
$ | 1,160,737 | | |
$ | 191,029 | |
General and administrative costs | |
| 1,138,748 | | |
| 607,113 | | |
| 531,635 | |
Total operating costs | |
| 2,490,514 | | |
| 1,767,850 | | |
| 722,664 | |
Loss from operations | |
| (2,490,514 | ) | |
| (1,767,850 | ) | |
| (722,664 | ) |
Other income (expense) | |
| 160,769 | | |
| (7,017 | ) | |
| 167,786 | |
Net loss | |
$ | (2,329,745 | ) | |
$ | (1,774,867 | ) | |
$ | (554,878 | ) |
| |
Three Months Ended September 30, | | |
Increase | |
| |
2023 | | |
2022 | | |
(Decrease) | |
Research and development costs by expense type: | |
| | |
| | |
| |
Salaries and payroll taxes | |
$ | 88,203 | | |
$ | 192,312 | | |
$ | (104,109 | ) |
Benefits | |
| 15,059 | | |
| 38,956 | | |
| (23,897 | ) |
Stock based compensation | |
| 185,785 | | |
| (16,896 | ) | |
| 202,681 | |
Clinical trial and other costs | |
| 1,062,719 | | |
| 946,365 | | |
| 116,354 | |
| |
$ | 1,351,766 | | |
$ | 1,160,737 | | |
$ | 191,029 | |
| |
Three
Months Ended September 30, | | |
Increase/ | |
| |
2023 | | |
2022 | | |
(Decrease) | |
General and administrative costs: | |
| | |
| | |
| |
Salaries and payroll taxes | |
$ | 103,936 | | |
$ | 74,662 | | |
$ | 29,274 | |
Benefits | |
| 7,190 | | |
| 6,216 | | |
| 974 | |
Legal | |
| 102,790 | | |
| 211,758 | | |
| (108,968 | ) |
Patent and trademark | |
| 26,314 | | |
| 8,998 | | |
| 17,316 | |
Insurance | |
| 288,066 | | |
| 17,765 | | |
| 270,301 | |
Facilities and rent | |
| 4,763 | | |
| 36,104 | | |
| (31,341 | ) |
Investor relations | |
| 48,671 | | |
| 32,498 | | |
| 16,173 | |
Accounting services | |
| 192,133 | | |
| 56,416 | | |
| 135,717 | |
Consulting services | |
| 103,424 | | |
| 18,411 | | |
| 85,013 | |
Other | |
| 96,077 | | |
| 86,678 | | |
| 9,399 | |
Stock-based compensation | |
| 165,384 | | |
| 57,607 | | |
| 107,777 | |
| |
$ | 1,138,748 | | |
$ | 607,113 | | |
$ | 531,635 | |
Three Months Ended September 30, 2023 Compared
to Three Months Ended September 30, 2022
Research and Development
expenses increased by 16.5%. Salaries and payroll taxes decreased by 54.1% from the third quarter of 2022 to the third quarter of 2023,
primarily due to the decrease in two headcount. Additionally, the CEO devoted more time towards general and administrative in 2023 due
to his work related to the IPO. Benefits decreased by 61.3% for these same reasons that salaries and payroll taxes decreased. Clinical
trial and other research costs increased by $116,354 primarily due to approximately $307,300 of costs in 2023 related to the manufacture
of our next batch of drug which is scheduled to occur in the fourth quarter of 2023. The Company also incurred approximately $164,100
of preliminary costs related to the Phase 3 study on Sarcoma in 2023. Costs related to Studies IT-01 and IT-02 decreased since their enrollments
were completed in June 2022 and August 2022, respectively. The increase in stock based compensation is predominantly due to the third
quarter of 2022 having a reduction of approximately $132,000 due to forfeited stock options.
General and Administrative
expenses increased by 87.6%. Salaries and payroll taxes increased by $29,274 due to a larger percentage of the CEO’s time being
spent on general and administrative activities and a salary increase to the Principal Accounting Officer. Legal expenses in 2022 include
costs related to an unsuccessful attempt at an IPO. Insurance increased due to the additional directors and officers’ insurance
as a publicly held company. Accounting services increased due to quarterly reviews and accounting services related to activities as a
publicly held company. Consulting service is predominantly the cost of our vice president of corporate finance.
Other income (expense) in
the third quarter of 2022 was predominantly interest expense on the convertible notes which were converted to common stock on June 29,
2023. Other income (expense) in the third quarter of 2023 was predominantly interest income earned on marketable debt securities and cash
and cash equivalents which increased in the third quarter of 2023 due to the proceeds from both the IPO and the sale of the overallotment
shares.
The deemed dividend represents
the value that was transferred to the Series B and C preferred stockholders upon triggering of anti-dilution provisions.
The following tables summarize
our results of operations for the nine months ended September 30, 2023 and 2022:
| |
Nine Months Ended September 30, | | |
Increase | |
| |
2023 | | |
2022 | | |
(Decrease) | |
Operating expenses: | |
| | |
| | |
| |
Research and development costs | |
$ | 2,984,752 | | |
$ | 4,241,203 | | |
$ | (1,256,451 | ) |
General and administrative costs | |
| 1,981,594 | | |
| 1,834,966 | | |
| 146,628 | |
Total operating costs | |
| 4,966,346 | | |
| 6,076,169 | | |
| (1,109,823 | ) |
Loss from operations | |
| (4,966,346 | ) | |
| (6,076,169 | ) | |
| 1,109,823 | |
Other income (expense) | |
| (2,400,412 | ) | |
| 4,613 | | |
| (2,405,025 | ) |
Net loss | |
$ | (7,366,758 | ) | |
$ | (6,071,556 | ) | |
$ | (1,295,202 | ) |
Preferred stock deemed dividend | |
| (1,323,535 | ) | |
| - | | |
| (1,323,535 | ) |
Net loss attributable to common shareholders | |
$ | (8,690,293 | ) | |
$ | (6,071,556 | ) | |
$ | (2,618,737 | ) |
| |
Nine Months Ended September 30, | | |
Increase | |
| |
2023 | | |
2022 | | |
(Decrease) | |
Research and development costs by expense type: | |
| | |
| | |
| |
Salaries and payroll taxes | |
$ | 368,050 | | |
$ | 860,975 | | |
$ | (492,925 | ) |
Benefits | |
| 64,448 | | |
| 144,007 | | |
| (79,559 | ) |
Stock based compensation | |
| 650,778 | | |
| 297,115 | | |
| 353,663 | |
Clinical trial and other costs | |
| 1,901,476 | | |
| 2,939,106 | | |
| (1,037,630 | ) |
| |
$ | 2,984,752 | | |
$ | 4,241,203 | | |
$ | (1,256,451 | ) |
| |
Nine
Months Ended September 30, | | |
Increase/ | |
| |
2023 | | |
2022 | | |
(Decrease) | |
General and administrative costs: | |
| | |
| | |
| |
Salaries and payroll taxes | |
$ | 274,283 | | |
$ | 231,469 | | |
$ | 42,814 | |
Benefits | |
| 15,659 | | |
| 17,172 | | |
| (1,513 | ) |
Legal | |
| 243,859 | | |
| 468,045 | | |
| (224,186 | ) |
Patent and trademark | |
| 59,798 | | |
| 34,266 | | |
| 25,532 | |
Insurance | |
| 321,766 | | |
| 58,717 | | |
| 263,049 | |
Facilities and rent | |
| 71,320 | | |
| 107,598 | | |
| (36,278 | ) |
Investor relations | |
| 115,227 | | |
| 132,740 | | |
| (17,513 | ) |
Accounting services | |
| 280,187 | | |
| 232,774 | | |
| 47,413 | |
Consulting services | |
| 137,907 | | |
| 139,814 | | |
| (1,907 | ) |
Other | |
| 136,944 | | |
| 168,153 | | |
| (31,209 | ) |
Stock-based compensation | |
| 324,644 | | |
| 244,218 | | |
| 80,426 | |
| |
$ | 1,981,594 | | |
$ | 1,834,966 | | |
$ | 146,628 | |
Nine Months Ended September 30, 2023 Compared
to Nine Months Ended September 30, 2022
Research and Development expenses decreased by 29.6%. Salaries and
payroll taxes decreased by 57.3% since 2022, predominantly due to four research employees leaving the Company from February 2022 through
June 2023. Benefits decreased by 55.2% for the same reason. Clinical trial and other research costs decreased by approximately $1.0 million
predominantly due to studies IT-01 and IT-02 that completed their enrollments in June 2022 and August 2022 respectively. The
end of enrollments resulted in a significant decrease in patient care costs. These decreases were slightly offset by the third quarter
of 2023 costs related to the new manufacturing batch as preliminary work on the Phase 3 Sarcoma study noted earlier. Stock based compensation
increased by approximately $353,700 because the nine months ended September 30, 2022 include a reduction of approximately $132,000 due
to forfeited options from a former employee and the options and warrants issued in December 2022.
General and Administrative
expenses increased by 8.0%. Salaries and payroll taxes increased by 18.5% due to a larger percentage of the CEO’s time being spent
on general and administrative activities and a salary increase to the Principal Accounting Officer. Legal expenses decreased by $224,186;
2022 had legal costs related to unsuccessful attempts at an IPO. Insurance increased due to the additional directors and officers’
insurance as a publicly held company. Facilities and rent decreased since we relocated our offices to a less expensive space that also
locates us closer to an area where we believe will have better employee recruitment.
Other income (expense) in
the first nine months of 2022 included interest expense on the convertible notes which were converted to common stock on June 29, 2023.
Other income (expense) in the first nine months of 2023 includes approximately $2.3 million loss on debt conversion at the time of the
IPO, plus $148,026 of interest income earned on marketable debt securities and cash and cash equivalents which increased in the third
quarter of 2023 due to the proceeds of both our IPO and the sale of overallotment shares.
The deemed dividend represents
the value that was transferred to the Series B and C preferred stockholders upon triggering of anti-dilution provisions.
Liquidity and Capital Resources
Since our inception, we have
not generated any revenue from product sales and have incurred significant operating losses. We expect to continue to incur significant
expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. We expect that
our research and development and general and administrative costs will continue to increase significantly, including in connection with
conducting clinical trials for our product candidates, developing our manufacturing capabilities and building and qualifying our manufacturing
facility to support clinical trials and commercialization and providing general and administrative support for our operations, including
the cost associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we
may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.
We do not currently have
any approved products and have never generated any revenue from product sales. We have financed our operations primarily through an initial
investment from our founder, the issuance and sale of convertible debt notes, the issuance and sale of private equity financings, and
an IPO, after which shares of our common stock began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “INTS”
on June 30, 2023. As of September 30, 2023, our cash and cash equivalents and investments in U.S. treasury bills were approximately $15.6
million. Based on our balances in cash, cash equivalents, and investments in U.S. treasury bills, we project to have sufficient cash to
fund our current operating plan until July 2025. This operating plan includes the increase in staffing such as the Vice President of Clinical
Operations and a manufacturing focused chemical engineer who began in September 2023.
The following table summarizes
the net cash provided by (used in) operating activities and financing activities for the periods indicated:
| |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Net cash (used in) operating activities | |
$ | (6,257,833 | ) | |
$ | (3,842,663 | ) |
Net cash (used in) investing activities | |
| (8,844,379 | ) | |
| - | |
Net cash provided by financing activities | |
| 20,484,160 | | |
| - | |
Net increase (decrease) in cash and cash equivalents | |
$ | 5,381,948 | | |
$ | (3,842,663 | ) |
Operating Activities
Net cash used in operating
activities for the nine months ended September 30, 2023 was approximately $6.3 million. This is primarily attributable to the loss of
approximately $7.4 million offset by: approximately $2.3 million for the non-cash loss on the conversion of convertible notes into shares
of common stock; approximately $1.0 million for the non-cash stock based compensation; an increase of approximately $0.9 million to prepaid
insurance expense, and a decrease in accounts payable and accrued expenses of approximately $1.6 million.
Net cash used in operating
activities for the nine months ended September 30, 2022 was predominantly the net loss of approximately $6.1 million. The predominant
differences between the approximately $6.1 million in operating loss and the approximately $3.8 million in net cash flows from operating
activities are approximately $0.5 million in non-cash stock compensation and approximately $1.6 million increase in accounts payable and
accrued expenses.
Investing Activities
The Company invested approximately
$8.8 million of the proceeds of both the IPO and sale of the overallotment shares in U.S. treasury bills with original maturities between
approximately 3 and 6 months.
There was no cash provided
by or used in investing activities for the nine months ended September 30, 2022.
Financing Activities
Net cash provided by financing
activities for the nine months ended September 30, 2023 consisted predominantly of approximately $22.4 million in gross proceeds
from both the IPO and sale of the overallotment shares, less underwriter fees and issuance costs of approximately $2.2 million. The Company
received approximately $243,000 from the sale of convertible notes prior to the IPO and $50,000 in proceeds from the exercise of warrants
and option.
There was no net cash provided
by financing activities for the nine months ended September 30, 2022.
Off-Balance Sheet Arrangements
We did not have any off-balance sheet
arrangements as of September 30, 2023.
Seasonality
Our business experiences
limited seasonality.
Critical Accounting Policies and Estimates
Our management’s discussion
and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our financial statements
and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs
and expenses, and the disclosure of contingent assets and liabilities in our financial statements. These items are monitored and analyzed
by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates
on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may materially differ from these
estimates under different assumptions or conditions.
While our significant accounting
policies are described in more detail in the notes to our financial statements included elsewhere in this report, we believe that the
following accounting policies are those most significant to the judgments and estimates used in the preparation of our financial statements.
Accrued Research and Development Expenses
Research and development
costs are expensed as incurred. We record the estimated patient care costs as services are provided but not yet invoiced and include these
costs in the accrued expenses in the balance sheet and within research other expense in the statement or operations.
Equity-Based Compensation
We recognize compensation
costs related to stock option grants to employees and board members and warrant grants to nonemployees based on the estimated fair value
of the awards on the date of grant. We estimate the grant date fair value and the resulting stock-based compensation expense using
the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is recognized on a straight-line basis
over the requisite service periods, which are generally the vesting period of the respective awards. Forfeitures are accounted for as
they occur.
We historically have been
a private company and lack company-specific historical and implied volatility information for our shares. Therefore, we estimate
our expected share price volatility based on the historical volatility of publicly traded peer companies and expect to continue to do
so until such time as we have adequate historical data regarding the volatility of our own traded share price.
JOBS Act Accounting Election
We are an “emerging
growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging
growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such
time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised
accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies.
Subject to certain conditions
set forth in the JOBS Act, if, as an “emerging growth company”, we choose to rely on such exemptions we may not be required
to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting
pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public
companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be
adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information
about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation
related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to
median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until
we are no longer an “emerging growth company,” whichever is earlier.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures
Historically, as a privately
held company, we have maintained internal controls over financial reporting but we have a material weakness due to a lack of segregation
of duties since we have a limited administrative staff. However, these internal controls have not been subject to the testing required
under the standards of publicly traded companies by Section 404 of Sarbanes-Oxley. We are not currently required to comply with SEC
rules that implement Section 404 of the Sarbanes-Oxley Act, and are therefore not required to make a formal assessment of the effectiveness
of our internal controls over financial reporting for that purpose. However, at such time as Section 404 of the Sarbanes-Oxley Act
is applicable to us, we will be required to evaluate our internal controls over financial reporting.
Evaluation of Disclosure
Controls and Procedures: We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that the information
required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the SEC’s rules and forms and such information is accumulated and communicated to management,
including the Chief Executive Officer, Executive Vice President of Corporate Finance, the Interim Chief Financial Officer (who is also
the Controller and Principal Accounting Officer) and two other independent financial consultants, as appropriate, to allow timely decisions
regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable
assurances of achieving the desired controls.
As of September 30,
2023, we carried out an evaluation, under the supervision and with the participation of our management, including the Chief Executive
Officer, Executive Vice President of Corporate Finance and the Interim Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures defined above. Based upon that evaluation, our Chief Executive Officer, Executive
Vice President of Corporate Finance and Interim Chief Financial Officer have concluded that, as of September 30, 2023, our disclosure
controls and procedures were not effective at the reasonable assurance level. In June 2023, the Company appointed an Interim Chief Financial
Officer and Executive Vice President of Corporate Finance, but there continues to be a lack of segregation of duties due to a limited
number of administrative employees and consultants resulting in a material weakness in internal controls.
In response to the above
identified weakness, we are taking the following remediation measures:
|
● |
We are reassessing our accounting procedures and, as part of the financial reporting process, plan to implement the use of supplementary checks and additional reviews and evaluations of transactions to improve the accuracy and reliability of our financial information. |
|
● |
We are adding appropriate resources to ensure that such procedures are implemented and adequate reviews are performed. |
Our Chief Executive Officer,
along with other key members of management, are and will be active participants in these remediation processes and such processes will
be subject to audit committee oversight. We believe these steps will improve the effectiveness of our internal controls. While we plan
to take the above steps to remediate these weaknesses, we cannot assure you that we will be able to fully remediate them, which could
impair our ability to accurately and timely meet our public company reporting requirements.
Limitations on the
Effectiveness of Controls Our management, including the Chief Executive Officer, Executive Vice President, Corporate Finance and
the Chief Financial Officer, recognizes that any set of controls and procedures, no matter how well-designed and operated, can provide
only reasonable, not absolute, assurance of achieving the desired control objectives. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the
inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances
of fraud, if any, with us have been detected. These inherent limitations include the realities that judgments in decision-making can
be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people or by management override of controls. For these reasons, internal control over
financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate. This lack of segregation of duties from a limited number of administrative employees is a material weakness
in internal controls. In our plan to start to address these weaknesses, in August 2021, the Company established a Chief Financial Officer
position through a consulting agreement with Danforth Advisors in order to add an additional layer of oversight on the financial reporting
process with assistance from another Danforth consultant to address this material weakness. In June 2023, to meet listing requirements
of Nasdaq, our Principal Accounting Officer and Controller, John Wesolowski, became our full-time Interim Chief Financial Officer
and James Ahlers became our Executive Vice President of Corporate Finance.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we are
made aware of legal allegations arising in the ordinary course of our business. We are not currently a party to any actions, claims, suits
or other legal proceedings the outcome of which, if determined adversely to Intensity, would individually or taken together have a material
adverse effect on our business, operating results, cash flows or financial condition.
Item 1A. Risk Factors
As of the date of this Quarterly
Report, other than the below, there have not been any material changes to the information related to the “Risk Factors” disclosure
in the Company’s Final Prospectus on Form 424(b)(4) dated June 29, 2023. Our business involves significant risks. You should carefully
consider the risks and uncertainties described in our Final Prospectus, together with all of the other information in this Quarterly Report
on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Final Prospectus. The risks
and uncertainties described in our prospectus are not the only ones we face.
Additional risk and uncertainties
that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization
of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results
of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price
of our common stock could decline and you could lose part or all of your investment.
The recent attack
by Hamas on Israel from the Gaza Strip could have an unpredictable effect on the global economy and on international and local securities
markets, and adversely affect our business and results of operations.
On October 7, 2023, Hamas
militants and members of other terrorist organizations infiltrated Israel’s southern border from the Gaza Strip and conducted a
series of terror attacks on civilian and military targets. Thereafter, these terrorists launched extensive rocket attacks on Israeli population
and industrial centers located along the Israeli border with the Gaza Strip. Shortly following the attack, Israel’s security cabinet
declared war against Hamas. The intensity and duration of Israel’s current war against Hamas is difficult to predict.
A downturn in the worldwide
economy resulting the recent attack by Hamas on Israel from the Gaza Strip and other conflicts with a global impact that may arise
from time to time could have a material adverse effect on our business, results of operations, and/or financial condition.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
INTENSITY THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/ Lewis H. Bender |
|
|
Lewis H. Bender |
|
|
President and Chief Executive Officer |
|
|
(principal executive officer) |
|
|
|
Date: November 13, 2023 |
|
|
|
|
|
|
By: |
/s/ John Wesolowski |
|
|
John Wesolowski |
|
|
Interim Chief Financial Officer,
Principal Accounting Officer and Controller |
|
|
(principal financial and accounting officer) |
|
|
|
Date: November 13, 2023 |
|
|
0.17
0.52
1.26
1.78
13660627
3410103
3410103
6899984
P5Y5M
false
--12-31
Q3
0001567264
0001567264
2023-01-01
2023-09-30
0001567264
2023-11-13
0001567264
2023-09-30
0001567264
2022-12-31
0001567264
us-gaap:RelatedPartyMember
2023-09-30
0001567264
us-gaap:RelatedPartyMember
2022-12-31
0001567264
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001567264
us-gaap:SeriesAPreferredStockMember
2022-12-31
0001567264
us-gaap:SeriesBPreferredStockMember
2023-09-30
0001567264
us-gaap:SeriesBPreferredStockMember
2022-12-31
0001567264
us-gaap:SeriesCPreferredStockMember
2023-09-30
0001567264
us-gaap:SeriesCPreferredStockMember
2022-12-31
0001567264
2023-07-01
2023-09-30
0001567264
2022-07-01
2022-09-30
0001567264
2022-01-01
2022-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-12-31
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-12-31
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-12-31
0001567264
us-gaap:CommonStockMember
2022-12-31
0001567264
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001567264
us-gaap:RetainedEarningsMember
2022-12-31
0001567264
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-09-30
0001567264
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0001567264
us-gaap:RetainedEarningsMember
2023-01-01
2023-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-09-30
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-09-30
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-09-30
0001567264
us-gaap:CommonStockMember
2023-09-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001567264
us-gaap:RetainedEarningsMember
2023-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-06-30
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-06-30
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2023-06-30
0001567264
us-gaap:CommonStockMember
2023-06-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001567264
us-gaap:RetainedEarningsMember
2023-06-30
0001567264
2023-06-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001567264
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001567264
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0001567264
us-gaap:CommonStockMember
2021-12-31
0001567264
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001567264
us-gaap:RetainedEarningsMember
2021-12-31
0001567264
2021-12-31
0001567264
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-09-30
0001567264
us-gaap:RetainedEarningsMember
2022-01-01
2022-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-09-30
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-09-30
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-09-30
0001567264
us-gaap:CommonStockMember
2022-09-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001567264
us-gaap:RetainedEarningsMember
2022-09-30
0001567264
2022-09-30
0001567264
ints:SeriesARedeemableConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-06-30
0001567264
ints:SeriesBConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-06-30
0001567264
ints:SeriesCConvertiblePreferredStockMember
us-gaap:PreferredStockMember
2022-06-30
0001567264
us-gaap:CommonStockMember
2022-06-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001567264
us-gaap:RetainedEarningsMember
2022-06-30
0001567264
2022-06-30
0001567264
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001567264
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001567264
us-gaap:IPOMember
2023-07-05
0001567264
2023-07-05
2023-07-05
0001567264
us-gaap:IPOMember
2023-07-05
2023-07-05
0001567264
us-gaap:OverAllotmentOptionMember
2023-07-07
0001567264
us-gaap:OverAllotmentOptionMember
2023-07-07
2023-07-07
0001567264
2023-04-01
2023-04-27
0001567264
us-gaap:CashEquivalentsMember
2023-09-30
0001567264
us-gaap:DebtSecuritiesMember
2023-09-30
0001567264
us-gaap:SeriesAPreferredStockMember
2023-01-01
2023-09-30
0001567264
us-gaap:SeriesAPreferredStockMember
2022-01-01
2022-09-30
0001567264
us-gaap:SeriesBPreferredStockMember
2023-01-01
2023-09-30
0001567264
us-gaap:SeriesBPreferredStockMember
2022-01-01
2022-09-30
0001567264
us-gaap:SeriesCPreferredStockMember
2023-01-01
2023-09-30
0001567264
us-gaap:SeriesCPreferredStockMember
2022-01-01
2022-09-30
0001567264
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-09-30
0001567264
us-gaap:EmployeeStockOptionMember
2022-01-01
2022-09-30
0001567264
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001567264
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001567264
ints:TwoThousandTwentyOneConvertibleNoteWithAShareholderMember
2021-09-20
0001567264
ints:TwoThousandTwentyOneConvertibleNoteWithAShareholderMember
2021-09-01
2021-09-20
0001567264
ints:TwoThousandTwentyOneConvertibleNoteWithAShareholderMember
2022-11-29
0001567264
ints:NovemberTwentyOneTwoThousandTwentyTwoConvertibleNotesWithShareholderOneMember
2022-11-21
0001567264
ints:NovemberTwentyOneTwoThousandTwentyTwoConvertibleNotesWithShareholderTwoMember
2022-11-21
0001567264
ints:NovemberTwentyOneTwoThousandTwentyTwoConvertibleNotesWithShareholdersMember
2022-11-01
2022-11-21
0001567264
ints:NovemberTwentyOneTwoThousandTwentyTwoConvertibleNotesWithShareholdersMember
2022-11-21
0001567264
ints:NovemberTwentyNineTwoThousandTwentyTwoConvertibleNotesWithShareholderMember
2022-11-29
0001567264
ints:NovemberTwentyNineTwoThousandTwentyTwoConvertibleNotesWithShareholderMember
2022-11-01
2022-11-29
0001567264
ints:MarchSixteenTwentyThousandTwentyThreeConvertibleNoteMember
2023-03-16
0001567264
ints:MarchThirtyTwoThousandTwentyThreeConvertibleNoteMember
2023-03-30
0001567264
ints:MarchThirtyTwoThousandTwentyThreeConvertibleNoteMember
2023-03-01
2023-03-30
0001567264
ints:AprilOneTwoThousandTwentyThreeConvertibleNoteMember
2023-04-01
0001567264
ints:AprilOneTwoThousandTwentyThreeConvertibleNoteMember
2023-04-01
2023-04-01
0001567264
ints:MayElevenTwoThousandTwentyThreeConvertibleNoteMember
2023-05-11
0001567264
ints:MayElevenTwoThousandTwentyThreeConvertibleNoteMember
2023-05-01
2023-05-11
0001567264
ints:JuneTwentyNineTwoThousandTwentyThreeConvertibleNotesWithShareholderOneMember
2023-01-01
2023-09-30
0001567264
ints:ConvertibleNoteDatedSeptemberTwentyTwentyThousandTwentyOneMember
2022-12-31
0001567264
ints:ConvertibleNotesDatedNovemberTwentyOneTwentyThousandTwentyTwoMember
2022-12-31
0001567264
ints:ConvertibleNoteDatedNovemberTwentyNineTwentyThousandTwentyTwoMember
2022-12-31
0001567264
us-gaap:CommonStockMember
us-gaap:IPOMember
2023-06-29
0001567264
us-gaap:IPOMember
2023-01-01
2023-09-30
0001567264
us-gaap:IPOMember
2023-07-01
2023-07-07
0001567264
us-gaap:IPOMember
2023-07-07
0001567264
srt:MinimumMember
2021-11-23
0001567264
srt:MaximumMember
2021-11-23
0001567264
ints:CommonStockWarrantsMember
2023-01-01
2023-01-01
0001567264
ints:CommonStockWarrantsMember
ints:TwoHoldersOfConvertibleNotesMember
2023-01-01
2023-01-01
0001567264
ints:CommonStockWarrantsMember
ints:TwoHoldersOfConvertibleNotesMember
2023-01-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:IPOMember
2023-01-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
2023-09-30
0001567264
ints:CommonStockWarrantsMember
2023-01-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
2021-12-31
0001567264
ints:CommonStockWarrantsMember
2022-01-01
2022-03-31
0001567264
ints:CommonStockWarrantsMember
2022-03-31
0001567264
ints:CommonStockWarrantsMember
2022-04-01
2022-06-30
0001567264
ints:CommonStockWarrantsMember
2022-06-30
0001567264
ints:CommonStockWarrantsMember
2022-07-01
2022-09-30
0001567264
ints:CommonStockWarrantsMember
2022-09-30
0001567264
ints:CommonStockWarrantsMember
2022-12-31
0001567264
ints:CommonStockWarrantsMember
2023-01-01
2023-03-31
0001567264
ints:CommonStockWarrantsMember
2023-03-31
0001567264
ints:CommonStockWarrantsMember
2023-04-01
2023-06-30
0001567264
ints:CommonStockWarrantsMember
2023-06-30
0001567264
ints:CommonStockWarrantsMember
2023-07-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:ResearchAndDevelopmentExpenseMember
2023-07-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:ResearchAndDevelopmentExpenseMember
2022-07-01
2022-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:GeneralAndAdministrativeExpenseMember
2023-07-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:GeneralAndAdministrativeExpenseMember
2022-07-01
2022-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-09-30
0001567264
ints:CommonStockWarrantsMember
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-09-30
0001567264
ints:CommonStockWarrantsMember
2022-01-01
2022-09-30
0001567264
ints:EmployeesOfficersDirectorsAndConsultantsMember
ints:TwoThousandAndThirteenPlanMember
2023-09-30
0001567264
srt:MinimumMember
ints:TwoThousandAndThirteenPlanMember
2023-09-30
0001567264
srt:MaximumMember
ints:TwoThousandAndThirteenPlanMember
2023-09-30
0001567264
ints:TwoThousandAndTwentyOnePlanMember
2023-01-01
2023-09-30
0001567264
ints:TwoThousandAndThirteenPlanMember
2023-09-30
0001567264
ints:TwoThousandAndTwentyOnePlanMember
2023-01-01
0001567264
2022-01-01
2022-03-31
0001567264
2022-03-31
0001567264
2022-04-01
2022-06-30
0001567264
2023-01-01
2023-03-31
0001567264
2023-03-31
0001567264
2023-04-01
2023-06-30
0001567264
ints:StockOptionsMember
2023-09-30
0001567264
ints:StockOptionsMember
2023-01-01
2023-09-30
0001567264
us-gaap:ResearchAndDevelopmentExpenseMember
2023-07-01
2023-09-30
0001567264
us-gaap:ResearchAndDevelopmentExpenseMember
2022-07-01
2022-09-30
0001567264
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-09-30
0001567264
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-09-30
0001567264
us-gaap:GeneralAndAdministrativeExpenseMember
2023-07-01
2023-09-30
0001567264
us-gaap:GeneralAndAdministrativeExpenseMember
2022-07-01
2022-09-30
0001567264
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-09-30
0001567264
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-09-30
0001567264
2017-01-31
0001567264
2018-11-30
0001567264
2020-07-31
0001567264
ints:WestportLeaseMember
2023-09-30
0001567264
2023-07-07
0001567264
ints:FirstSixMonthsMember
2023-07-01
2023-07-07
0001567264
ints:NextSixMonthsMember
2023-07-01
2023-07-07
0001567264
ints:LastTwelveMonthsMember
2023-07-01
2023-07-07
0001567264
ints:SheltonLeaseMember
2023-01-01
2023-09-30
0001567264
ints:YearOneMember
2023-01-01
2023-09-30
0001567264
ints:YearTwoMember
2023-01-01
2023-09-30
0001567264
ints:YearThreeMember
2023-01-01
2023-09-30
0001567264
ints:YearFourMember
2023-01-01
2023-09-30
0001567264
ints:YearFiveMember
2023-01-01
2023-09-30
0001567264
ints:YearSixMember
2023-01-01
2023-09-30
0001567264
2022-01-01
2022-12-31
0001567264
us-gaap:DomesticCountryMember
2023-09-30
0001567264
us-gaap:StateAndLocalJurisdictionMember
2023-09-30
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
utr:sqft
utr:sqm